Moving Biotech Products from CBER to CDER: A Work in Progress

Article

Special Issues

LCGC SupplementsSpecial Issues-07-01-2006
Volume 0
Issue 0

A slow, steady process of transitioning biologicals has allayed industry concerns.

External Link - article-416324.pdf

Articles in this issue
Analytical Instrument Qualification
GMP and Phase I Clinical Trials: Streamlining the Critical Path?
GMP and Phase I Clinical Trials: Streamlining the Critical Path?
Team Effort
Team Effort
Rated PG: Pharmaceutical Guidance Suggested
Rated PG: Pharmaceutical Guidance Suggested
European Clinical Trial Regulations Undergo a Slow Revolution
European Clinical Trial Regulations Undergo a Slow Revolution
A Practical and Cost-Effective Risk Assessment for the Validation of Commercial Laboratory Computerized Systems
A Practical and Cost-Effective Risk Assessment for the Validation of Commercial Laboratory Computerized Systems
Moving Biotech Products from CBER to CDER: A Work in Progress
Moving Biotech Products from CBER to CDER: A Work in Progress
FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chief
New Climate
New Climate
2006: A Regulatory Odyssey
2006: A Regulatory Odyssey
CDER?s Division of Post-Marketing Evaluation for Quality Assessment
CDER?s Division of Post-Marketing Evaluation for Quality Assessment
Better Compliance Through Technology
Better Compliance Through Technology
Good Clinical Practice Q&A
Good Clinical Practice Q&A
Keeping Pace
Keeping Pace
The Growing Regulatory Burden and Revolution in Global Clinical Trials
The Growing Regulatory Burden and Revolution in Global Clinical Trials
Recent Videos
Related Content
Sports doping, anabolic capsule - shape of a male muscular upper body - symbol for medical drug abuse. | Image Credit: © Andy Shell - stock.adobe.com

GC/C/IRMS Applied to Develop Doping Control Analysis Method

Aaron Acevedo
December 3rd 2024
Article

Shanghai University of Sport scientists recently developed a doping control method based on gas chromatography combustion isotope ratio mass spectrometry (GC/C/IRMS).

Ep. 31: Clarifying the Meaning of Chemometrics, Artificial Intelligence (AI), Machine Learning (ML), and Neural Networks (NNs)

Ep. 31: Clarifying the Meaning of Chemometrics, Artificial Intelligence (AI), Machine Learning (ML), and Neural Networks (NNs)

December 2nd 2024
Podcast
Rubber Seals Gaskets | Image Credit: © markobe - stock.adobe.com

EAS Session Highlights GC/MSD and High-Resolution GC/Q-TOF for Volatile Extractables and Leachables

Aaron Acevedo
December 2nd 2024
Article

A scientist from Agilent Technologies spoke about research analyzing extractables and leachables identified in rubber gasket extracts.

Ep. 30: The Potential of Generative Artificial Intelligence as a Research Assistant for Measurement Science

Ep. 30: The Potential of Generative Artificial Intelligence as a Research Assistant for Measurement Science

November 1st 2024
Podcast
The LCGC Blog: Teaching Separations to the Next Generation of Instrumentalists

The LCGC Blog: Teaching Separations to the Next Generation of Instrumentalists

Katelynn A. Perrault Uptmor
December 2nd 2024
Article

In this LCGC Blog, Katelynn Perrault Uptmor discusses her time teaching undergraduates separation science, and what she and her students have learned through their time together.

RAFA 2024: Rudolf Krska Discusses Quantifying Mycotoxins and Secondary Metabolites in Plants and Foods

RAFA 2024: Rudolf Krska Discusses Quantifying Mycotoxins and Secondary Metabolites in Plants and Foods

Alasdair Matheson
November 29th 2024
Article

As part of our RAFA 2024 coverage, we interviewed Rudolf Krska of BOKU University about his research on food safety, specifically regarding using analytical methods to mycotoxins and other secondary metabolites in plants and foods.